Miller-Dieker Syndrome (MDS) is a rare and severe neurodevelopmental disorder characterized by a smooth brain surface (lissencephaly), facial abnormalities, and profound developmental delays. But thanks to advances in medical science, there’s growing momentum in both early diagnosis and innovative care strategies. br br 🔬 What’s Fueling Market Growth? br br Increased awareness and screening for chromosomal disorders is enabling earlier diagnoses and timely interventions. br br Breakthroughs in genetic diagnostics, especially high-resolution microarrays and sequencing, are making it easier to identify MDS and other structural abnormalities. br br A growing wave of neurodevelopmental research is unlocking the mechanisms behind MDS, paving the way for potential treatments. br br 🧪 Emerging Therapies & Innovations: br br CRISPR-Cas9 gene editing is being studied for its potential to correct underlying genetic causes—though it's still in early research. br br Supportive care like anti-seizure medications, physical therapy, and respiratory support continues to improve the quality of life for patients. br br Assistive devices tailored for neurological impairments are further enhancing day-to-day functioning. br br 🤝 Collaborative efforts between biotech companies, research institutions, and regulatory bodies are fostering new therapeutic strategies and funding more clinical trials in this rare disease space. br br Report Link: br br Contact us: br br IMARC Group br 134 N 4th St., Brooklyn, br NY 11249, USA br Email: sales@imarcgroup.com br Tel No:(D) +91 120 433 0800 br United States: +1-631-791-1145 br Follow us on LinkedIn: br br ✨ Subscribe to learn more about rare diseases, the power of genetics, and the science reshaping future care.